Some diabetes drugs tied to increased risk of cancer, says report
Filed under: All Cancers
According to a new report out of the University of Vermont, patients with diabetes who take thiazolidinediones, which include Avandia and Actos, have an increased risk of developing cancer. This association was only seen in women and was not statistically significant in men.
Dr. Maria Ramos-Nino and colleagues examined the relationship between thiazolidinediones and cancer prevalence among nearly 9,000 diabetic patients. The team found that the use of any thiazolidinedione was associated with a 59 percent increased risk of cancer. The use of Avandia increased the risk by 89 percent, where the risk associated with Actos was not statistically significant.
The researchers could not explain why these risk numbers were so different for the two drugs, since they are thought to work by the same mechanism.
On the other hand, the use of sulfonylurea by women was associated with a 51 percent decreased risk of cancer.
The authors acknowledge that the study had several limitations and do not recommend changing any clinical decisions involving these drugs at this time.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Patricia Mayville-Cox
No comments yet. Be the first.
Leave a reply
Some diabetes drugs tied to increased risk of cancer, says report
Filed under: All Cancers
According to a new report out of the University of Vermont, patients with diabetes who take thiazolidinediones, which include Avandia and Actos, have an increased risk of developing cancer. This association was only seen in women and was not statistically significant in men.
Dr. Maria Ramos-Nino and colleagues examined the relationship between thiazolidinediones and cancer prevalence among nearly 9,000 diabetic patients. The team found that the use of any thiazolidinedione was associated with a 59 percent increased risk of cancer. The use of Avandia increased the risk by 89 percent, where the risk associated with Actos was not statistically significant.
The researchers could not explain why these risk numbers were so different for the two drugs, since they are thought to work by the same mechanism.
On the other hand, the use of sulfonylurea by women was associated with a 51 percent decreased risk of cancer.
The authors acknowledge that the study had several limitations and do not recommend changing any clinical decisions involving these drugs at this time.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Patricia Mayville-Cox
No comments yet. Be the first.
Leave a reply